Lupin Achieves FDA Approval for Modafinil Tablets Targeting Sleep Disorders
Lupin Receives FDA Approval for Modafinil Tablets
In a significant milestone for the global pharmaceutical landscape, Lupin Limited has announced the recent approval from the U.S. Food and Drug Administration (FDA) for its Modafinil Tablets, available in dosages of 100 mg and 200 mg. This approval corresponds to an Abbreviated New Drug Application (ANDA) and signifies the product's bioequivalence to the reference listed drug, Provigil®, manufactured by Nuvo Pharmaceuticals (Ireland) DAC.
Indication and Market Value
The newly approved Modafinil Tablets are indicated to enhance wakefulness in adult patients experiencing excessive sleepiness linked to conditions such as narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). The market for Provigil® was estimated to reach annual sales of approximately $70.7 million in the U.S., highlighting the potential for Lupin's entry in addressing these critical health issues.
About Lupin
Headquartered in Mumbai, India, Lupin Limited stands as a prominent player in the pharmaceutical industry, extending its reach across the U.S., developed markets, and emerging economies with products available in over 100 markets worldwide. The company boasts a diversified portfolio that includes generics, complex generics, specialty medicines, and biosimilars, alongside a robust commitment to sustaining its market position through product differentiation.
Lupin maintains strong leadership within its core therapeutic areas, which encompass cardiovascular health, respiratory conditions, diabetes management, gastrointestinal health, and women's health. The company’s operations are backed by 15 advanced manufacturing facilities and 6 dedicated research centers, with more than 26,000 professionals contributing to its mission.
Commitment to Healthcare and Sustainability
Lupin is not just focused on expanding its product portfolio; it also aims to enhance the overall healthcare ecosystem. The company is actively involved in various initiatives such as diagnostics, digital health solutions, patient support programs, and disease management efforts. Furthermore, sustainability remains a vital pillar of its business strategy, ensuring that health advancements happen alongside environmental responsibility.
Conclusion
The FDA's approval of Lupin’s Modafinil Tablets is a major step forward, promising improved treatment options for individuals suffering from excessive sleepiness due to various health conditions. This development not only reflects Lupin's commitment to innovation but also its strategic focus on enhancing patient care across the globe.
For more information about Lupin and its extensive range of products, visit www.lupin.com or follow the company on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.